Long ED Waits Tied to Extended Hospital Stays

BY BRUCE K. DIXON

Chicago Bureau

CHICAGO — Extended emergency department waiting times significantly elevated hospital costs and, for the large subset of patients with congestive heart failure, extended hospital stays, according to a single-hospital study led by Dr. Bram Dolcourt.

"If a patient waits in our emergency room for 8 hours or longer, that person

will end up with an additional \$6,000 in total hospital charges," said Dr. Dolcourt, of Henry Ford Hospital in Detroit.

Based on that finding, Dr. Dolcourt estimated that extended ED waits cost Henry Ford Hospital nearly \$2 million annually.

Although length of stay for the top 20 admitting diagnoses combined was not significantly affected by ED waits of more than 8 hours, congestive heart failure (CHF) by itself stood out.

"Interestingly, for CHF—which is the

No. 1 admitting diagnosis in our ED—patients who stayed longer than 8 hours stayed in the hospital 3 additional days," Dr. Dolcourt said. Causation is unclear, he added, and may reflect other factors associated with long bed waits.

This retrospective study included 1,747 patients aged 18 years or older admitted through the ED with one of the top 20 admitting diagnoses to a general practice unit from July to December 2005. It was presented as a poster at the annual meet-

ing of the Society for Academic Emergency Medicine. Patients were assessed for time spent waiting for a bed after a bed re-



A patient who waits in our ED for 8 hours or longer will end up with an additional \$6,000 in total hospital charges.

DR. DOLCOURT

quest was made, hospital length of stay, and total hospital charges.

Prolonged ED lengths of stay were based on an a priori cutoff of 4 hours; however, after data analysis, 8 hours represented 1 standard deviation above the mean (which was approximately 4 hours).

"Although our results may not apply to other hospitals, these findings underscore the importance of looking at our processes and finding areas where we can speed aspects of admission and discharge so that, hopefully, we can reduce costs and lengths of stay," Dr. Dolcourt said. Waiting times most likely are more of a symptom than a cause, he concluded.

Experience the evolution of cancer information.



The world's leading medical publisher introduces a professional website for trusted oncology information.

- Search and download recent articles from over I00 Elsevier cancer related journals
- Daily summaries of articles from leading society journals like JCO, JNCI, CA, Blood, JAMA and NEJM
- Professional drug monographs, interactions, chemotherapy regimens and patient handouts
- Videos, blogs, forums and much more
- Guided by an esteemed Advisory Board that includes four past presidents of ASCO

World class resources. All in one place.

Register today at www.oncologystat.com



INDEX OF ADVERTISERS

Tracleer	16a-16b
Aetna Inc. Corporate	13
Bayer HealthCare LLC	
Aspirin	43
Bayer HealthCare/Johnson & Johnson Ph Research & Development Clinical Trial	armaceutical
Boehringer Ingelheim Pharmaceuticals,	
Flomax	
Bristol-Myers Squibb Sanofi Pharmaceut Corporate	14-15
Discovery Health CME	7
Forest Pharmaceuticals, Inc.	
Lexapro	4a-4b, 5
Corporate	24a-24b
Namenda	34a-34b
Eli Lilly and Company	
Cymbalta	54-56
Merck & Co., Inc.	
Janumet	8a-8d, 9
Fosamax	11-12
Zostavax	44a-44c
Novartis Pharmaceuticals Corporation	
Exelon	3
Reclast	22a-22h
Exforge	39-40
Novo Nordisk Inc.	
Levemir	33-34
Corporate	36
NovoLog Mix 70/30	47-48
P&G	
Prilosec OTC	10
Pfizer Inc.	
Exubera	20a-20b
Celebrex	28-31
Reliant Pharmacueticals, Inc.	
Lovaza	18-20
Sanofi-Aventis U.S. LLC	
Lantus SoloSTAR	40a-40b
Sepracor Inc. Brovana	36a-36b